# Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

> **NCT04213937** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 386 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT04213937
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-31
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 386 (ESTIMATED)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213937, "Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04213937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*